Atlas Trials

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Clinical trial NCT03433703 · TERMINATED

Trial details

NCT number
NCT03433703
Sponsor
Eisai Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Carcinoma, Hepatocellular
Start date
2018-04-26
Primary completion
2019-01-07
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.